RT Journal Article
T1 Locoregional treatments before liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry.
A1 Pommergaard, Hans-Christian
A1 Rostved, Andreas Arendtsen
A1 Adam, René
A1 Thygesen, Lau Caspar
A1 Salizzoni, Mauro
A1 Gómez Bravo, Miguel Angel
A1 Cherqui, Daniel
A1 De Simone, Paolo
A1 Boudjema, Karim
A1 Mazzaferro, Vincenzo
A1 Soubrane, Olivier
A1 García-Valdecasas, Juan Carlos
A1 Fabregat Prous, Joan
A1 Pinna, Antonio D
A1 O'Grady, John
A1 Karam, Vincent
A1 Duvoux, Christophe
A1 Rasmussen, Allan
A1 European Liver and Intestine Transplant Association (ELITA), 
K1 hepatocellular carcinoma
K1 liver transplantation
K1 locoregional treatment
K1 pretreatment
AB Locoregional treatment while on the waiting list for liver transplantation (Ltx) for hepatocellular carcinoma (HCC) has been shown to improve survival. However, the effect of treatment type has not been investigated. We investigate the effect of locoregional treatment type on survival after Ltx for HCC. We investigated patients registered in the European Liver Transplant Registry database using multivariate Cox regression survival analysis. Information on locoregional therapy was registered for 4978 of 23 124 patients and was associated with improved overall survival [hazard ratio (HR) 0.84 (0.73-0.96)] and HCC-specific survival [HR 0.76 (0.59-0.98)]. Radiofrequency ablation (RFA) was the one monotherapy associated with improved overall survival [HR 0.51 (0.40-0.65)]. In addition, the combination of RFA and transarterial chemoembolization also improved survival [HR 0.74 (0.55-0.99)]. Adjusting for factors related to prognosis, disease severity, and tumor aggressiveness, RFA was highly beneficial for overall and HCC-specific survival. The effect may represent a selection of patients with favorable tumor biology; however, the treatment may be effective per se by halting tumor progression. Clinicaltrials.gov number: NCT02995096.
YR 2018
FD 2018-02-21
LK http://hdl.handle.net/10668/12061
UL http://hdl.handle.net/10668/12061
LA en
DS RISalud
RD Apr 20, 2025